Guest: Malcolm Bell, MD
Host: Sharonne Hayes, MD
Overview:
In this podcast, we talk about the rationale for shortening the length of twin antiplatelet remedy after coronary stenting and persevering with P2Y12 inhibitor instead of persevering with aspirin as monotherapy. With this method, the chance of serious bleeding is diminished considerably and with no corresponding improve in ischemic or thrombotic occasions. This technique is especially enticing for sufferers who’re thought of to be at high-risk of bleeding or that suffer an actionable bleed. A P2Y12 inhibitor seems to extra efficacious for long run secondary prevention than aspirin.
Questions:
1. We know that sufferers present process coronary stenting require twin antiplatelet remedy for various durations. Recently, we now have heard that of some fascinating adjustments in using twin remedy so what’s new?
a. Some background context
b. Impact of bleeding
c. Strategy of “Short DAPT” monotherapy with a P2Y12 inhibitor
2. Tell us extra about Short DAPT and dropping the aspirin – this appears fairly radical. Is it secure?
3. When and during which sufferers would you turn to monotherapy with a P2Y12 inhibitor?
a. High bleeding danger sufferers
b. Actionable bleeds
c. Stable CAD vs ACS
4. Is there a selected P2Y12 inhibitor you’d select?
a. Brief response
5. What do you do after 6 or 12 months of monotherapy – proceed, or change again to aspirin?
a. Brief response
